Arcturus Therapeutics Holdings Inc (NAS:ARCT)
$ 17.9 -0.74 (-3.97%) Market Cap: 484.87 Mil Enterprise Value: 297.15 Mil PE Ratio: 0 PB Ratio: 1.85 GF Score: 77/100

Arcturus Therapeutics Holdings Inc at Canaccord Genuity Growth Conference Transcript

Aug 09, 2023 / 01:30PM GMT
Release Date Price: $28.42 (+10.45%)
Joohwan Kim
Canaccord Genuity Group Inc. - Analyst

Hi, everyone. Hi, everyone. Welcome and thanks for attending Canaccord Genuity's 43rd Annual Growth Conference. My name is Joohwan Kim, and I'm an associate on Whitney Ijem's genetic medicine and rare disease team. We're very excited to have the team from Arcturus Therapeutics here. It's my great pleasure to introduce the President and CEO, Mr. Joseph Payne. Arcturus is a global-stage mRNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. And so with that, I'll turn it over to the team for their presentation.

Joseph Payne
Arcturus Therapeutics Holdings Inc. - President, CEO & Director

All right, thank you. We'll go ahead. That was an appropriate introduction. The Arcturus is a messenger RNA medicines and vaccines company. I remember a couple of years ago, we used to spend quite a bit of time explaining what messenger RNA is. But now, because of the COVID pandemic, and everyone's been vaccinated, there's a lot more

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot